Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Portal   Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA


Groupe Français de Cytogénétique Oncologique (GFCO)



Created in 1992, following the GFCH (Groupe Français de Cytogénétique Hématologique ), the GFCO federates several french laboratories involved in solid tumor cytogenomics. Since 2008 it is working group of the ACLF (Association des Cytogénéticiens de Langue Française), itself a member of the FFGH (Fédération Française de Génétique Humaine), the global french human genetic association also born in 2008.

The aim is to organize 3 meetings a year so that hospital cytogeneticists, clinicians, and researchers have : the opportunity to meet each other to share experience and results obtained in each laboratory, to provide information about new items, to drive cooperative studies. Our working method of revision of each cytogenetic file during the workshops is a guarantee of quality. A quality assessement scheme and participations to various good practice protocols is an other activity.

On going prospective scientific studies of the GFCO are the following :

  • tumours of the kidney (apart from non papillary) (chair J Couturier)
  • involvement of clinical aCGH in solid tumors.
  • the GFCO supports the Atlas and is part of the referring process of the Atlas.

    Chair Dr Alain Bernheim
    Laboratoire de Cytogénétique
    FRE 2939 CNRS, Institut Gustave Roussy,
    39 rue Camille Desmoulins
    94805 Villejuif Cedex, France.
    Tel. 33 (1) 45-59-54-15.
    email: bernheim@igr.fr

  • Bernheim A, Vagner-Capodano A, Couturier J, Oncologique GFdC. De la cytogénétique à la cytogénomique oncologique. Médecine/Sciences 2000;16:528-39.
  • Huret JL, Dessen P, Bernheim A. Atlas of Genetics and Cytogenetics in Oncology and Haematology, updated. Nucleic Acids Res 2001;29:303-4.
  • Leonard C, Huret JL, Gfco. [From cytogenetics to cytogenomics of bladder cancers]. Bull Cancer 2002;89:166-73.
  • Pedeutour F, Foa C. [From cytogenetics to cytogenomics of adipose tissue tumors: 1. Benign adipose tissue tumors]. Bull Cancer 2002;89:689-95.
  • Perissel B, Bernheim A, Couturier J, Fouilhoux G, Vago P. [From the cytogenetics to the cytogenomics of thyroid tumors]. Bull Cancer 2002;89:588-92.
  • Vagner-Capodano AM, Zattara-Cannoni H, Quilichini B, Giocanti G. [From cytogenetics to cytogenomics of brain tumors: 1. Medulloblastoma]. Bull Cancer 2003;90:315-8.
  • Pedeutour F, Maire G, Sirvent N. [From cytogenetics to cytogenomics of adipose tissue tumors: 2. Malignant adipose tissue tumors]. Bull Cancer 2004;91:317-23.

    Participation to:

  • Hastings RJ, Cavani S, Bricarelli FD, Patsalis PC, Kristoffersson U. Cytogenetic Guidelines and Quality Assurance: a common European framework for quality assessment for constitutional and acquired cytogenetic investigations. Eur J Hum Genet 2007;15:525-7.